Form 4: Exelixis CEO Michael Morrissey Acquires Shares Through Performance-Based Vesting

Exelixis CEO Michael Morrissey acquired 473,226 shares of common stock through performance-based vesting, while also disposing of shares to cover tax obligations.

Summary

• Exelixis CEO Michael Morrissey received 473,226 shares of common stock on January 16, 2025, as part of a performance-based restricted stock unit (PSU) award.
• The PSU was initially granted on March 4, 2022, and allowed for vesting of up to 175% of the target shares based on performance criteria.
• The Compensation Committee certified the achievement of certain performance criteria on January 16, 2025, resulting in the vesting of 50% of the achieved shares immediately.
• An additional 50% of the achieved shares will vest on February 15, 2026, contingent on continued service.
• 120,244 shares were disposed of to cover tax obligations related to the vesting of the PSU at a price of $37.27 per share.
• Following these transactions, Morrissey directly owns 1,089,936 shares and indirectly owns 1,587,000 shares through a family trust and 17,728 shares through a 401(k) plan.

Sentiment

Score: 7

Explanation: The document reflects a positive event (vesting of performance-based shares) and a neutral event (tax-related share disposal). The overall sentiment is moderately positive as it indicates the company met performance targets.

Positives

• The vesting of performance-based stock units indicates that the company has met certain performance criteria set by the Compensation Committee.
• The CEO's increased share ownership aligns his interests with those of the shareholders.

Negatives

• The sale of 120,244 shares to cover tax obligations, while a normal practice, does reduce the CEO's overall shareholding.

Risks

• The future vesting of the remaining 50% of the achieved shares is contingent on the CEO's continued service through February 15, 2026.

Future Outlook

The remaining 50% of the achieved shares will vest on February 15, 2026, subject to the CEO's continued service.

Industry Context

This filing is a routine disclosure of executive stock transactions, which is common in publicly traded companies. It reflects the company's compensation structure and performance-based incentives.

Comparison to Industry Standards

• Performance-based equity awards are a common practice in the biotechnology industry to align executive compensation with company performance.
• The vesting schedule of the PSU, with a portion vesting upon performance achievement and the remainder vesting later, is a typical structure.
• The sale of shares to cover tax obligations is a standard practice for executives receiving equity compensation.

Stakeholder Impact

• Shareholders may view the vesting of performance-based shares positively, as it indicates the company met performance targets.
• The CEO's increased share ownership aligns his interests with those of the shareholders.

Next Steps

• The remaining 50% of the achieved shares will vest on February 15, 2026, contingent on the CEO's continued service.

Key Dates

Keywords

Exelixis, Michael Morrissey, stock vesting, performance-based units, PSU, share ownership, executive compensation, SEC Form 4